Firmonertinib mesylate

Overview

Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-112870A
• CAS No.: 2130958-55-1
• Molecular Formula: C29H35F3N8O5S
• Molecular Weight: 664.70
• Purity: 99.97%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 0.5 mg/mL (0.75 mM); Clear solution
• Availability: In-stock

Source

Original product source